Artelo Biosciences, Inc. is working to meet Nasdaq's requirements to maintain its stock listing, with a deadline to show compliance by March 30, 2026, particularly needing to report a stockholder equity of at least $2,500,000; this follows past deficiencies communicated on November 19, 2025.